Advanced Ovarian Carcinoma Clinical Trials

9 recruiting

Advanced Ovarian Carcinoma Trials at a Glance

10 actively recruiting trials for advanced ovarian carcinoma are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Jacksonville, Boston, and Durham. Lead sponsors running advanced ovarian carcinoma studies include M.D. Anderson Cancer Center, Mayo Clinic, and Dana-Farber Cancer Institute.

Browse advanced ovarian carcinoma trials by phase

Treatments under study

About Advanced Ovarian Carcinoma Clinical Trials

Looking for clinical trials for Advanced Ovarian Carcinoma? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Ovarian Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Ovarian Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Not Applicable

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Carcinoma+4 more
Dana-Farber Cancer Institute240 enrolled6 locationsNCT06710548
Recruiting
Phase 3

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Stage IV Ovarian Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Advanced Ovarian Carcinoma+22 more
M.D. Anderson Cancer Center580 enrolled19 locationsNCT04575935
Recruiting
Early Phase 1

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

Recurrent Ovarian CarcinomaStage III Ovarian Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8+2 more
Ohio State University Comprehensive Cancer Center161 enrolled1 locationNCT07144826
Recruiting
Phase 1

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+71 more
M.D. Anderson Cancer Center43 enrolled1 locationNCT05092373
Recruiting
Phase 2

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Advanced Ovarian CarcinomaAdvanced Fallopian Tube CarcinomaAdvanced Primary Peritoneal Carcinoma+15 more
Mayo Clinic78 enrolled3 locationsNCT06639074
Recruiting
Phase 1

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

Metastatic Renal Cell CarcinomaMetastatic Ovarian CarcinomaMetastatic Pancreatic Carcinoma+5 more
Molecure S.A.40 enrolled3 locationsNCT05759923
Recruiting
Phase 1

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Pancreatic CancerGastric CancerGastroesophageal Junction Adenocarcinoma+1 more
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled1 locationNCT05472857
Recruiting
Phase 2

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastroesophageal Junction Adenocarcinoma+30 more
Northwestern University94 enrolled1 locationNCT05733000